Postoperative nausea and vomiting after total thyroidectomy: sevoflurane combined with prophylactic ramosetron vs. propofol-based total intravenous anesthesia.
10.4097/kjae.2014.66.3.216
- Author:
Sang Hee PARK
1
;
Hyung Gon LEE
;
Chang Young JEONG
;
Seong Wook JEONG
;
Seong Heon LEE
;
Hwi Jin KIM
Author Information
1. Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School, Gwangju, Korea. leehg@chonnam.ac.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Postoperative nausea and vomiting;
Propofol;
Ramosetron;
Thyroidectomy
- MeSH:
Adult;
Analgesics;
Anesthesia, General;
Anesthesia, Intravenous*;
Antiemetics;
Female;
Humans;
Incidence;
Postoperative Nausea and Vomiting*;
Propofol;
Prospective Studies;
Thyroidectomy*
- From:Korean Journal of Anesthesiology
2014;66(3):216-221
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The frequent and distressing adverse events (AEs) of postoperative nausea and vomiting (PONV) are of major concern in 63-84% of adult patients undergoing thyroidectomy. We conducted this prospective study to compare two prophylactic strategies; sevoflurane combined with ramosetron and propofol-based total intravenous anesthesia in a homogenous group of non-smoking women undergoing total thyroidectomy. METHODS: In the current prospective study, we enrolled a consecutive series of 64 female patients aged between 20 and 65 years with an American Society of Anesthesiologists physical status of I or II who were scheduled to undergo elective total thyroidectomy under general anesthesia. Patients were randomized to either the SR (sevoflurane and remifentanil) group or the TIVA group. We evaluated the incidence and severity of PONV, the use of rescue anti-emetics and the severity of pain during the first 24 h after surgery. RESULTS: There were no significant differences in the proportion of the patients with a complete response and the Rhodes index, including the occurrence score, distress score and experience score, between the two groups. In addition, there were no significant differences in the proportion of the patients who were in need of rescue anti-emetics or analgesics and the VAS scores between the two groups. CONCLUSIONS: In conclusion, TIVA and ramosetron prophylaxis reduced the expected incidence of PONV in women undergoing total thyroidectomy. In addition, there was no significant difference in the efficacy during the first 24 h postoperatively between the two prophylactic regimens.
